Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTOFYT1)

• DTT Name: Prostacyclin receptor (PTGIR) DTT Info
• Gene Name: PTGIR

Molecule-Related Drug & Molecule List

7 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprost Tromethamine	DMXQKSL	Abortion	JA00	Approved	[1]
Epoprostenol	DMUTYR2	Allergic rhinitis	CA08.0	Approved	[2]
Misoprostol	DMHVJFK	Medical abortion	JA00.1Z	Approved	[1]
Selexipag	DMAHSU0	Pulmonary arterial hypertension	BB01.0	Approved	[3]
Treprostinil	DMTIQF3	Pulmonary arterial hypertension	BB01.0	Approved	[4]
Beraprost	DML634R	Pulmonary hypertension	BB01	Phase 4	[5]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[6]

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
esuberaprost	DMXLGED	Gout	FA25	Phase 3	[7]
Ralinepag	DM7G4Y9	Pulmonary arterial hypertension	BB01.0	Phase 2	[8]

6 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clinprost	DM6E5VA	Asthma	CA23	Discontinued in Preregistration	[9]
Ataprost	DMPTG39	Asthma	CA23	Discontinued in Phase 3	[10]
YM533	DMFEN6T	Chronic renal failure	GB61.Z	Discontinued in Phase 3	[11]
OP-2507	DMQM4OV	Hypertension	BA00-BA04	Discontinued in Phase 2	[12]
AP-227	DM7LAXF	N. A.	N. A.	Terminated	[13]
EPTALOPROST	DM2NHLW	Solid tumour/cancer	2A00-2F9Z	Terminated	[14]

15 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AFP-07	DM4WVMU	Discovery agent	N.A.	Investigative	[15]
BAY-73-1449	DM5CPJ2	Discovery agent	N.A.	Investigative	[16]
BMY 45778	DMT02B8	Discovery agent	N.A.	Investigative	[17]
butaprost (free acid form)	DM5MZHP	Discovery agent	N.A.	Investigative	[18]
carbacyclin	DMMBQYE	Discovery agent	N.A.	Investigative	[18]
cicaprost	DM7ZJ4H	Discovery agent	N.A.	Investigative	[19]
EP 157	DMSPIF2	Discovery agent	N.A.	Investigative	[20]
FR-181157	DM2V7U1	Discovery agent	N.A.	Investigative	[21]
FR-193262	DM9BS3W	Discovery agent	N.A.	Investigative	[22]
isocarbacyclin	DMZR7W6	Discovery agent	N.A.	Investigative	[19]
Prostacyclin analog	DMXCJ7O	Pulmonary hypertension	BB01	Investigative	[11]
RO1138452	DMAOI51	Discovery agent	N.A.	Investigative	[23]
RO3244794	DMBFCKD	Discovery agent	N.A.	Investigative	[23]
TEI-9063	DMGQLYR	Discovery agent	N.A.	Investigative	[17]
U46619	DM13FX4	Discovery agent	N.A.	Investigative	[18]

References

• [1] Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58.
• [2] Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94.
• [3] Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80.
• [4] Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35.
• [5] Prostaglandin I2 IP Receptor Agonist, Beraprost, Prevents Transient Global Cerebral Ischemia Induced Hippocampal CA1 Injury in Aging Mice. J Neurol Disord. 2014;2:1000174.
• [6] Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
• [7] Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittelforschung. 1989 Apr;39(4):495-9.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Protective effect of a prostaglandin I2 analog, TEI-7165, on ischemic neuronal damage in gerbils. Brain Res. 1997 Sep 26;769(2):321-8.
• [10] Pharmacokinetics of intravenous ataprost alfadex, a new prostaglandin I2 analog in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1993 Aug;31(8):373-5.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 345).
• [12] Effect of a prostaglandin I(2) analog on the expression of thrombomodulin in liver and spleen endothelial cells after an extensive hepatectomy. Surg Today. 2011 Feb;41(2):230-6.
• [13] Molecular design of novel PGI2 agonists without PG skeleton, Bioorg. Med. Chem. Lett. 5(10):1071-1076 (1995).
• [14] Bioactivation of eptaloprost in animals and man. Prostaglandins. 1993 Aug;46(2):177-89.
• [15] 7,7-Difluoroprostacyclin derivative, AFP-07, a highly selective and potent agonist for the prostacyclin receptor. Prostaglandins. 1997 Feb;53(2):83-90.
• [16] Vascular actions of the prostacyclin receptor antagonist BAY 73-1449 in the portal hypertensive rat. Eur J Pharmacol. 2008 Aug 20;590(1-3):322-6.
• [17] Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol. 1997 Apr;29(4):525-35.
• [18] The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
• [19] Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
• [20] Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics. Br J Pharmacol. 1986 Mar;87(3):543-51.
• [21] Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4861-4.
• [22] Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3279-83.
• [23] RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol. 2006 Feb;147(3):335-45.